Skip to main content
Home / Current Molecular Pharmacology, Volume 6, Number 3

Therapeutical Potential of CB2 Receptors in Immune-Related Diseases

Buy Article:

$68.00 + tax (Refund Policy)

The cannabinoid receptor CB2 is highly expressed in immune cells suggesting an important role in numerous diseases such as inflammation, cancer, osteoporosis and liver diseases relating to modulation of the immune system. As a consequence, activation of receptor CB2 is a promising therapeutic strategy for the treatment of a large range of diseases. Indeed, selective CB2 agonists display beneficial anti-inflammatory, anti-cancer and antifibrogenic properties and positive effects on liver disease and osteoporosis. This article reviews the CB2 involvement in the immune system and the promising therapeutical potential of selective CB2 agonists in the treatment of several immune-related diseases.

Keywords: Analgesic; CB2 agonists; anti-inflammatory; anticancer; antifibrogenic; cannabinoid receptors; immune system; immune-related diseases; liver disease; osteoporosis

Document Type: Research Article

Publication date: 01 November 2013

More about this publication?

  • Current Molecular Pharmacology aims to publish the latest developments in cellular and molecular pharmacology with a major emphasis on the mechanism of action of novel drugs under development, innovative pharmacological technologies, cell signaling, transduction pathway analysis, genomics, proteomics, and metabonomics applications to drug action. An additional focus will be the way in which normal biological function is illuminated by knowledge of the action of drugs at the cellular and molecular level. The journal publishes expert reviews , original reserach articles and thematic issues on molecular pharmacology.

    Current Molecular Pharmacology is an essential journal for every scientist who is involved in drug design and discovery, target identification, target validation, preclinical and clinical development of drugs therapeutically useful in human disease.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites

Share Content

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content